Company intelligence / Profile preview
Everon Biosciences
Buffalo, NY, USAeveronbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Everon Biosciences has demonstrated robust preclinical efficacy of small molecule and immunotherapeutic candidates in animal models, showing reduced frailty index and lifespan extension of 25–30%. Its most advanced clinical asset (RAPATAR), an mTOR inhibitor, has reached Phase 1 trials for reperfusion injury, with other programs in preclinical development.
- Therapeutic areas
- CardiovascularOther
- Modalities
- Small moleculeBiologicImmunotherapeutic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Roswell Park Cancer Institute
Beyond the preview
Go deeper on Everon Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Everon Biosciences.